Shivam Tyagi

The author works as a Correspondent with BW Businessworld

Latest Articles By Shivam Tyagi

Glenmark Settles Class Action Lawsuit In US Court Related With Drug Zetia For $87.5 Mn

Shivam Tyagi

On Tuesday Glenmark Pharmaceuticals stated in an exchange filing that it has agreed to enter into a settlement with the three plaintiff groups who had filed a class action lawsuit against the company in the US court for a total amount of USD 87.5 million related to the generic drug Zetia

Manufacturing Components For Medical Devices Big Challenge In India: Chaitanya Sarawate

Shivam Tyagi

Economy

In an exclusive interaction with BW Healthcare World, Chaitanya Sarawate, President and CEO-India & South Asia, GE Healthcare and Managing Director, Wipro-GE, speaks on key digital pillars for healthcare, Chat GPT, reducing import dependence of Indian Medtech, leveraging ER&D and future plans of his company

The Whole System Has To Change For Outcome Based Payments: Dr Ashutosh Raghuvanshi

Shivam Tyagi

Economy

In an exclusive interaction with BW Businessworld, Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare delineates on the growth of the hospital industry, outcome based payment model, slashing costs, PPP models and the hospital chain’s plans for expansion & acquisitions

Hurting Generic Industry Compelling Pharma To Spend More On R&D

Shivam Tyagi

Economy

Industry experts contend that largely the research budgets of the top firms have remained flattish in the last two to three years on account of Covid, but the scenario might be changing for some select firms like Sun Pharmaceuticals, Dr Reddy’s Labs, Zydus Lifesciences, Cipla and Biocon Biologics among others due a hurting generic pharma industry

India Must Focus On Biopharmaceuticals To Feed The Growth Engine: Kiran Mazumdar Shaw

Shivam Tyagi

Economy

In an exclusive conversation with BW Healthcare World, Kiran Mazumdar Shaw, Executive Chairperson, Biocon & Biocon Biologics delineates on how Indian pharma can move up the value chain, while also speaking on Biocon's R&D investments and future plans

E-pharmacies Might Go Down, Industry Expert Says Shutting Shops Not A Solution

Shivam Tyagi

Economy

Online pharmacies in India like Tata 1mg, Netmeds and Pharmeasy among others are in troubled waters again as media reports say that the pharmacies might face a complete ban over the online sale of drugs for alleged violation of norms

Rethinking Procurement Strategy of Healthcare Institutions

Shivam Tyagi

Economy

Indian medical technology industry is moving in the right direction with exciting times ahead although the sector needs improvements in many aspects and still has a long way to go to reduce the 80 to 85 per cent import dependency of the Indian healthcare system when it comes to using medical devices in hospitals and diagnostic labs

Single Drug Regulatory Framework

Shivam Tyagi

Healthcare

Chennai-based drug firm, Global Pharma Healthcare, voluntarily recalled its whole batch of eye drops after the USFDA notification alleged that they had caused a death and 55 instances of eye infections and permanent loss of vision

Biocon Reports Net Loss Of Rs 42 Cr, Sales Up By 36% YoY In Q3FY23

Shivam Tyagi

Economy

Biocon's revenue for the third quarter stood at Rs 3,020 crores against Rs 2,223 crores in the same quarter last year. Whereas the company posted a net loss of Rs 42 crores in quarter three of the financial year 2023(Q3FY23

BW Exclusive | Price Erosion In US Hurting Generic Pharma Industry Says RK Baheti, CFO, Alembic Pharma

Shivam Tyagi

Economy

In an exclusive interaction with BW Healthcare World, RK Baheti, CFO, Alembic Pharmaceuticals speaks on the headwinds for generics, the progress of PLI schemes in pharma, updates on the USFDA inspections, takeaways from the budget and the company's outlook in the upcoming financial year